Skip to content
 

Taylor Wimpey: is this shaping up to be Q2’s turnaround story?

*

The Armchair Trader pick: Tactical Portfolio

  • Taylor Wimpey (LSE:TW)
  • Sector: Home Construction
  • Market cap: GBP 4.8bn
  • Entry price: 134.2p
  • 3 year high: 231p
  • Target price: 200p
  • Stop loss: 10% (trailing)

We were eventually forced to exit our position in Bellway Homes as the share price breached our trailing stop loss. But we remain very keen on some of the bigger players in the UK house building space, hence our addition of Taylor Wimpey (LSE:TW) this week to our pick list. Taylor Wimpey looks like a great stock, but the shares have been shedding value since it peaked in April last year.

There remains an active debate on the house building sector, with many commentators wondering why these stocks remain at these prices. Taylor Wimpey shares are now at levels last seen in November 2020. Yet the demand for housing in the UK remains a major and pressing concern.


Want the full story? Access all of The Armchair Trader's content for just £5.99 per month.

Get weekly investment ideas and tips that will take your investing to the next level. Sign up here.

Free 28 day trial. Cancel anytime.


Log In or Sign Up to Armchair Trader+

Already a member? Log in here:


Not a member yet? Sign up for your free trial or check out the benefits of membership.

Further content of this article is not available as it is for members only. Please visit the registration page for Armchair Trader Plus+ for further details on the benefits of becoming a member.

Like this article? Sign up to our free newsletter.

This article does not constitute investment advice. Do your own research or consult a professional advisor.

'How to' Guides

Our latest in-depth company reports

Detailed reviews of selected companies and investment trusts.

On the podcast

Sign up for great investing stock tips

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

Aquis
FP Markets
Pepperstone
WisdomTree
CME Group
Back To Top